Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 17/20 | 0.77 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5042325 | 1.00 | SLC6A2 (0.77) | SLC6A2SLC6A4CYP2D6KCNH2GRIN1 | |
| SCHEMBL5449237 | 1.00 | SLC6A2 (0.77) | SLC6A2SLC6A4CYP2D6KCNH2GRIN1 | |
| Hydrochloric Acid SCHEMBL5048024 | 0.99 | SLC6A2 (0.77) | SLC6A2SLC6A4CYP2D6KCNH2GRIN1 | |
| Hydrochloric Acid SCHEMBL5048021 | 0.99 | SLC6A2 (0.77) | SLC6A2SLC6A4CYP2D6KCNH2GRIN1 | |
| Hydrochloric Acid SCHEMBL5433729 | 0.99 | SLC6A2 (0.77) | SLC6A2SLC6A4CYP2D6KCNH2GRIN1 | |
| SCHEMBL6469426 | 0.87 | SLC6A2 (1.00) | SLC6A2SLC6A4HTR1A | |
| SCHEMBL14595288 | 0.87 | SLC6A2 (1.00) | SLC6A2SLC6A4HTR1A | |
| SCHEMBL8283440 | 0.87 | SLC6A2 (1.00) | SLC6A2SLC6A4HTR1A | |
| SCHEMBL6438236 | 0.87 | SLC6A2 (1.00) | SLC6A2SLC6A4HTR1A | |
| Hydrochloric Acid SCHEMBL5042313 | 0.86 | SLC6A2 (1.00) | SLC6A2SLC6A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY A CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20060241188-A1 | Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY (US) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241188-A1 | Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors | SLC6A2, SLC6A3, SLC6A4 | SLC6A2 1/4885SLC6A4 3/4885CYP2D6 231/4885 |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | SLC6A2, SLC6A4, SLC6A3 | SLC6A2 1/4885SLC6A4 2/4885CYP2D6 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.